A Randomized Controlled Trail of Allicin in the Treatment of Medium-later Period Primary Liver Cancer

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR-IPR-15007452

Enrollment

Unknown

Registered

2015-11-24

Start date

2015-11-24

Completion date

Unknown

Last updated

2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Primary Hepatocellular Carcinoma

Interventions

Experimental group:Drug, allicin, PO, 40mg Tid.

Control group:None

Eligibility

Sex/Gender

All

Age

18 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1. Primary liver cancer(Barcelona stage B-C) diagnosed by imaging examination or pathological examination and unable to be operated; 2. KPS score >60; 3. Expected to survive more than 3 months; 4. Child-Pugh grade A or B; 5. Age range from 1870 years old; 6. Blood, urine and feces three routine parameters are generally normal, the function of heart, lung and kidney are generally normal, CRE=3*10^9/L; NEU>=1.5*10^9/L; HB>=80g/L; 7. Not associated with hypertension, diabetes, heart disease and other fatal diseases; 8. With hypertension, diabetes, heart disease and other fatal diseases, but will not threaten the lives of patients in short term. The lifetime expected more than 3 months; 9. Not accompanied by other malignant tumors; 10. Volunteered to accept this treatment and with good compliance.

Exclusion criteria

Exclusion criteria: 1. There were no more than 2 weeks since the last anticancer therapy (such as systemic chemotherapy, interventional therapy, local radiotherapy etc.); 2. KPS score <=60; 3. Child-Pugh grade level C, Barcelona stage D; 4. Patients associated with hypertension, diabetes, heart disease and other deadly diseases. The lives of patients will be threatened in the short time and the expected survival time is less than or equal to 3 months; 5. Accompanied with other malignant tumor; 6. Combined with mental disorders and other mental diseases; 7. Poor compliance; 8. Severe infection; 9. Other conditions that the researchers consider inappropriate.

Design outcomes

Primary

Measure	Time frame
hepatic parameters;tumor size;AFP;ECOG grade;KPS grade;PT;Clinical symptoms;	—

Secondary

Measure	Time frame
Blood routine;Blood coagulation;progression-free survival;overall survival;disease control rate;objective response rate;	—

Countries

China

Contacts

Public ContactLiu Qinghua

lqhwll@hotmail.com+86 15299967920

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026